Indivior Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Sep 17, 2024TrialINDV-6001 Multiple-Dose Pharmacokinetic Study

Aug 7, 2024FDASelincro — ZURNAI (AUTOINJECTOR)

Jun 10, 2024TrialProof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Jul 10, 2023TrialSingle Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

May 23, 2023FDASuboxone — BRIXADI

May 22, 2023FDASelincro — OPVEE

Mar 16, 2023TrialStudy of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

Mar 1, 2023TrialEvaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

4 more events

Aug 17, 2022TrialStudy to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Oct 26, 2021TrialBuprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Jul 6, 2020TrialINDV-2000 First in Human

Oct 21, 2019TrialSUBLOCADE Rapid Initiation Extension Study

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

9 patent groups across drugs · Source: FDA Orange Book

DrugExpires

SuboxoneJul 31, 2026 SuboxoneJan 10, 2027 Suboxone8 patentsJun 6, 2031 Suboxone8 patentsJan 6, 2032 Suboxone3 patentsNov 6, 2035 SuboxoneJun 22, 2038 SelincroJul 10, 2038 Selincro2 patentsNov 5, 2039

1 more

SelincroAug 4, 2042

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Suboxone — BUPRENEX

Application NDA018401 (NDA)

19951 event

FDAApr 17

Selincro — REVEX

Application NDA020459 (NDA)

20021 event

FDAOct 8

Suboxone — SUBUTEX

Application NDA020732 (NDA)

20101 event

FDAJun 30

Suboxone — BUTRANS

Application NDA021306 (NDA)

20151 event

FDAOct 23

Suboxone — BELBUCA

Application NDA207932 (NDA)

20161 event

FDAMay 26

Suboxone — PROBUPHINE

Application NDA204442 (NDA)

20171 event

FDANov 30

Suboxone — SUBLOCADE

Application NDA209819 (NDA)

20232 events

FDAMay 23

Suboxone — BRIXADI

Application NDA210136 (NDA)

FDAMay 22

Selincro — OPVEE

Application NDA217470 (NDA)

20241 event

FDAAug 7

Selincro — ZURNAI (AUTOINJECTOR)

Application NDA218590 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)